Apotex Health Corp's latest earnings report reveals a significant miss, raising questions about its growth trajectory.
In its recent earnings for the quarter ending June 30, 2026, Apotex Health Corp (APTX.TO) reported an earnings per share (EPS) of -0.19, which is much lower than the analyst estimate of -0.01. This disappointing result reflects a surprise percentage of -1800.0%, continuing a trend of missed expectations for the company.
Recent earnings trend
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeAdvertisement
Market cap
$8.62B
P/E
22.8x
52W high
$40.18
52W low
$26.05
1W change
-4.77%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 15.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.24
+15.5% Upside
Current Price
C$35.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
51.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$42.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$37.90 | C$32.00 – C$44.88 |
| 60 trading days | C$40.22 | C$31.67 – C$51.09 |
| 90 trading days | C$42.69 | C$31.85 – C$57.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 10 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-11 | — | 0.4100 | — |
| 2026-06-30 | 2026-08-12 | -0.1900 | -0.0100 | -1800.0% |
Advertisement
Investor takeaway: For Canadian investors, Apotex's substantial earnings miss highlights the volatility and unpredictability of the pharmaceutical sector, especially as the company navigates its recent IPO and ongoing market pressures.
Bull case
Despite the earnings miss, analysts maintain a bullish consensus rating for Apotex Health Corp, with an average target price of C$41.24. This suggests there could be potential upside from its current trading levels. The company's recent IPO and market presence might set the stage for future growth.
Bear case
The significant earnings miss raises concerns about Apotex's operational efficiency and its ability to manage costs effectively. Investors may need to rethink their positions if the company doesn't show improved financial performance in the upcoming quarters.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
